ADSC-Derived Extracellular Vesicles Loaded with VEGF mRNA Delivered by Antibacterial Hydrogel Promote Angiogenesis and Reconstruction of Prefabricated Flaps.
Wang Y., Zhang Y., Zhou L., Li Y., Zu X., Zhang J.
Animal Study, published in Small (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Small (2025)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41170665
- DOI
- 10.1002/smll.202508210
- Citations
- 1
Abstract (original English)
Prefabricated flaps often suffer from distal necrosis due to ischemia, with no clinically effective prevention or treatment currently available. Although extracellular vesicles (EVs) derived from adipose-derived stem cells (ADSCs) have shown pro-angiogenic potential, their therapeutic efficacy alone remains limited. In this study, VEGF mRNA is successfully encapsulated within ADSCs-derived EVs, which subsequently exhibit pro-angiogenic effects on cultured human umbilical vein endothelial cells (HUVECs). To enable sustained release, a biocompatible tannic acid-based hydrogel (TA-Gel) is developed with tunable mechanical properties and antimicrobial activity. This hydrogel significantly enhances both flap viability and vascular regeneration in vivo when combined with VEGF-EVs. Transcriptome sequencing reveals that VEGF-EVs@TA-Gel upregulates differentially expressed genes (DEGs) involved in VEGF-related pro-angiogenesis, collagen response, and anti-oxidative stress pathways. Moreover, 16S rRNA sequencing confirms that VEGF-EVs@TA-Gel inhibits the growth of common pathogenic bacteria, including Escherichia coli and Pseudomona. Collectively, these findings indicate that VEGF-EVs@TA-Gel promotes the survival and quality of prefabricated flaps through the sustainable release of VEGF mRNA-loaded EVs.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.